TY - JOUR T1 - Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 695 LP - 699 DO - 10.2967/jnumed.120.251751 VL - 62 IS - 5 AU - Matthew D. Bucknor AU - Daphne Y. Lichtensztajn AU - Tracy K. Lin AU - Hala T. Borno AU - Scarlett L. Gomez AU - Thomas A. Hope Y1 - 2021/05/10 UR - http://jnm.snmjournals.org/content/62/5/695.abstract N2 - The purpose of this study was to evaluate differences between patients receiving 18F-fluciclovine and 68Ga-prostate-specific membrane antigen (68Ga-PSMA-11) for biochemically recurrent prostate cancer at a tertiary medical center. Methods: All 18F-fluciclovine and 68Ga-PSMA-11 PET studies performed at the University of California San Francisco from October 2015 to January 2020 were reviewed. Age, race/ethnicity, primary language, body mass index, insurance type, and home address were obtained through the electronic medical record. A logistic regression model was used to evaluate the predictor variables. Results: In total, 1,502 patients received 68Ga-PSMA-11 and 254 patients received 18F-fluciclovine. Black patients had increased odds of receiving imaging with 18F-fluciclovine versus 68Ga-PSMA-11 compared with non-Hispanic White patients (odds ratio, 3.88; 95% CI, 1.90–7.91). There were no other statistically significant differences. Conclusion: In patients receiving molecular imaging for prostate cancer at a single U.S. tertiary medical center, access to 68Ga-PSMA-11 for Black patients was limited, compared with non-Hispanic White patients, by a factor of nearly 4. ER -